Drug intelligence / Profile preview

CS93108

Development stage: Preclinical
Lead developer: Akeso
Modality: Small Molecules

Overview

CS93108 is a preclinical-stage small molecule inhibitor of Tyrosine Kinase 2 (TYK2) being developed by Chipscreen NewWay, a subsidiary of Shenzhen Chipscreen Biosciences. TYK2 is a member of the Janus kinase (JAK) family that mediates signaling for cytokines such as IL-23, IL-12, and Type I interferons, which are critical in the pathogenesis of various autoimmune and inflammatory conditions. By selectively inhibiting TYK2, CS93108 aims to modulate these inflammatory pathways while potentially avoiding the side effects associated with broader JAK1/2/3 inhibition. The drug is currently being investigated for the treatment of autoimmune diseases.

Targets

TYK2 (Tyrosine kinase 2)

Beyond the preview

Go deeper on CS93108.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CS93108.

Explore the full profile